Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6h-pyrimido(1,6-b)pyridazin-6-one,5-(2,6-dichlorophenyl)-2-(phenylthio)-
2. Vx-745
1. 209410-46-8
2. Vx-745
3. 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6h-pyrimido[1,6-b]pyridazin-6-one
4. Vx 745
5. Vx745
6. 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one
7. Vrt-031745
8. Neflamapimod [usan]
9. 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6h-pyrimido[1,6-b]pyridazin-6-one
10. Vd-31745
11. Vd-31,745
12. Tyl52qm320
13. Chebi:90528
14. 5-(2,6-dichlorophenyl)-2-[2,4-difluorophenyl)thio]-6h-pyrimido[1,6-b]pyridazin-6-one
15. Neflamapimod (usan)
16. 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)-thio)-6h-pyrimido[1,6-b]pyridazin-6-one
17. 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6h-pyrimido[1,6-b]pyridazin-6-one
18. 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6h-pyrimido(1,6-b)pyridazin-6-one
19. 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylsulfanyl)-6h-pyrimido[3,4-b]pyridazin-6-one
20. 6h-pyrimido(1,6-b)pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-
21. 6h-pyrimido[1,6-b]pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-
22. C19h9cl2f2n3os
23. Hexadecylacrylate
24. Kinome_3767
25. Neflamapimod [inn]
26. Unii-tyl52qm320
27. Mls006010281
28. Neflamapimod [who-dd]
29. Schembl156367
30. Chembl119385
31. Gtpl5719
32. Bdbm15244
33. Cid_3038525
34. Dtxsid90175115
35. Ex-a854
36. Bcpp000015
37. Hms3295m13
38. Hms3654l10
39. Hms3884m17
40. Vd-31
41. Bcp01837
42. Ac-707
43. Mfcd09834070
44. Nsc785334
45. S1458
46. Zinc13493055
47. Akos005766014
48. Am84727
49. Ccg-269082
50. Cs-0195
51. Db07138
52. Ex-8451
53. Nsc-785334
54. Sb19425
55. 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyridazino[6,1-f]pyrimidin-6-one
56. Ncgc00241111-01
57. Ncgc00241111-02
58. Ncgc00241111-12
59. Hy-10328
60. Smr004701351
61. Db-000564
62. Vx-745, >=98% (hplc)
63. Ft-0654042
64. Sw219693-1
65. D10959
66. 410v468
67. 5t-0205
68. A815037
69. J-013730
70. J-516084
71. Brd-k91900765-001-01-9
72. Q27089208
73. 5-(2,6-dichloro-phenyl)-2-(2,4-difluoro-phenylsulfanyl)-1,7,8a-triaza-naphthalen-6-one
74. 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6h-pyrimido[1,6-a]pyridazin-6-one
75. 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-6-pyrimido[1,6-b]pyridazinone
76. 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]pyrimido[1,6-b]pyridazin-6-one
77. 5-(2,6-dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6h-pyrimido(1,6-b)pyridazine-6-one
78. 5-(2,6-dichlorophenyl)-9-(2,4-difluorophenyl)sulfanyl-1,3,10-triazabicyclo[4.4.0]deca-2,5,7,9-tetraen-4-one
79. 5-[2,6-bis(chloranyl)phenyl]-2-[2,4-bis(fluoranyl)phenyl]sulfanyl-pyrimido[1,6-b]pyridazin-6-one
| Molecular Weight | 436.3 g/mol |
|---|---|
| Molecular Formula | C19H9Cl2F2N3OS |
| XLogP3 | 5.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 434.9811448 g/mol |
| Monoisotopic Mass | 434.9811448 g/mol |
| Topological Polar Surface Area | 70.3 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 762 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Neflamapimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neflamapimod, including repackagers and relabelers. The FDA regulates Neflamapimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neflamapimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Neflamapimod supplier is an individual or a company that provides Neflamapimod active pharmaceutical ingredient (API) or Neflamapimod finished formulations upon request. The Neflamapimod suppliers may include Neflamapimod API manufacturers, exporters, distributors and traders.
Neflamapimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neflamapimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Neflamapimod GMP manufacturer or Neflamapimod GMP API supplier for your needs.
A Neflamapimod CoA (Certificate of Analysis) is a formal document that attests to Neflamapimod's compliance with Neflamapimod specifications and serves as a tool for batch-level quality control.
Neflamapimod CoA mostly includes findings from lab analyses of a specific batch. For each Neflamapimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neflamapimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Neflamapimod EP), Neflamapimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neflamapimod USP).
LOOKING FOR A SUPPLIER?
